Johnson and Johnson has stopped clinical trials of its test Covid vaccine more than “an unexplained ailment” in one of the study’s participants, the organization declared Monday.
“We have briefly delayed further dosing in the entirety of our COVID-19 antibody up-and-comer clinical trials, including the Phase 3 ENSEMBLE preliminary, because of an unexplained trial in a study participant,” the company wrote in an announcement.
The company didn’t disclose any insights regarding the detailed disease, yet said the member is being evaluated by an interior checking board and doctors.
“We should regard this current member’s privacy. We’re also becoming familiar with this current member’s disease, and it’s critical to have the real factors before we share extra data,” Johnson and Johnson wrote.
The study pause was first reported by Stat News.
The company said in its statement that illnesses during clinical trials are not uncommon.
“Adverse events – illnesses, accidents, etc. – even those that are serious, are an expected part of any clinical study, especially large studies.”
